Eloxx Pharmaceuticals Reports Q3 GAAP EPS of -$0.49, Exceeding Estimates

Eloxx Pharmaceuticals (ELOX) reported third-quarter GAAP earnings per share of -$0.49, which outperformed analyst expectations by $0.09. Despite the net loss, the company's earnings performance showed better-than-anticipated results for the period. As of September 30, 2026, the company held $56.3 million in cash and cash equivalents, a slight decrease from the $62.0 million reported at the end of June 2026. Management expressed confidence in their liquidity position, stating that current cash reserves are expected to fund operations through 2028.

By https://seekingalpha.com/user/52365730/bio · Seeking Alpha ·

Eloxx Pharmaceuticals Reports Q3 GAAP EPS of -$0.49, Exceeding Estimates

Topics: cash_runway earnings_beat financial_results

Read the full article at Seeking Alpha

More World news